What is William Blair’s Forecast for Hologic Q3 Earnings?

Hologic, Inc. (NASDAQ:HOLX) – William Blair lifted their Q3 2026 earnings per share estimates for Hologic in a report released on Friday, November 7th. William Blair analyst A. Brackmann now expects that the medical equipment provider will post earnings of $1.14 per share for the quarter, up from their previous estimate of $1.13. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. William Blair also issued estimates for Hologic’s Q4 2026 earnings at $1.19 EPS.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating the consensus estimate of $1.10 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same quarter last year, the firm earned $1.01 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis.

A number of other brokerages have also recently weighed in on HOLX. BTIG Research reiterated a “neutral” rating on shares of Hologic in a research report on Tuesday, October 21st. Argus lifted their target price on shares of Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a report on Friday, September 19th. Wall Street Zen lowered Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Morgan Stanley raised their price target on Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 31st. Finally, Leerink Partners lifted their price objective on Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a research note on Tuesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat.com, Hologic currently has an average rating of “Hold” and a consensus target price of $79.23.

Hologic Trading Up 0.3%

HOLX opened at $74.30 on Monday. The stock has a market capitalization of $16.53 billion, a PE ratio of 30.83, a P/E/G ratio of 2.54 and a beta of 0.65. Hologic has a one year low of $51.90 and a one year high of $80.31. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The business’s 50 day moving average price is $69.13 and its 200 day moving average price is $65.32.

Institutional Trading of Hologic

Institutional investors have recently modified their holdings of the stock. Chung Wu Investment Group LLC purchased a new position in shares of Hologic in the 2nd quarter valued at $26,000. Winnow Wealth LLC acquired a new position in Hologic in the third quarter valued at $26,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares during the last quarter. Root Financial Partners LLC purchased a new position in shares of Hologic during the third quarter worth about $27,000. Finally, SJS Investment Consulting Inc. increased its position in shares of Hologic by 341.5% during the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 362 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Activity

In related news, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the sale, the director owned 47,336 shares in the company, valued at $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the transaction, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.88% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.